Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy
The telehealth company will now offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are approved by the FDA.
This is a brief. The reporting belongs to CNBC — read the complete story, with full context and credits, at the source.
Read the full story at CNBC ↗cnbc.com
More from the Business desk
Just in
The AI power scramble is in full force. Which companies really stand to profit?
Just in

Anthropic: The seven founders who are about to become multi-billionaires
Just in

A Massachusetts Town Revolts Against Amazon’s Delivery Drones
Just in
